This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Telmisartan

Read time: 1 mins
Marketing start date: 22 Nov 2024
...
 

Summary of product characteristics


Effective Time

20221031

Version

7

Spl Product Data Elements

telmisartan telmisartan TELMISARTAN TELMISARTAN FERRIC OXIDE RED LACTOSE MONOHYDRATE MAGNESIUM STEARATE MEGLUMINE POVIDONE SODIUM HYDROXIDE SODIUM STEARYL FUMARATE SORBITOL MOTTLED LIGHT BROWN TO MOTTLED BROWN ROUND 471 telmisartan telmisartan TELMISARTAN TELMISARTAN SODIUM HYDROXIDE MEGLUMINE POVIDONE LACTOSE MONOHYDRATE FERRIC OXIDE RED SORBITOL SODIUM STEARYL FUMARATE MAGNESIUM STEARATE MOTTLED LIGHT BROWN TO MOTTLED BROWN OBLONG 472 telmisartan telmisartan TELMISARTAN TELMISARTAN SODIUM HYDROXIDE MEGLUMINE POVIDONE LACTOSE MONOHYDRATE FERRIC OXIDE RED SORBITOL SODIUM STEARYL FUMARATE MAGNESIUM STEARATE MOTTLED LIGHT BROWN TO MOTTLED BROWN OBLONG 473

Application Number

ANDA203325

Brand Name

Telmisartan

Generic Name

telmisartan

Product Ndc

65841-805

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-804-05 in bottle of 500 tablets Telmisartan Tablets USP, 20 mg R x only 500 tablets NDC 65841-805-05 in bottle of 500 tablets Telmisartan Tablets USP, 40 mg R x only 500 tablets NDC 65841-806-05 in bottle of 500 tablets Telmisartan Tablets USP, 80 mg R x only 500 tablets Telmisartan tablets, 20 mg Telmisartan Tablets, 40 mg Telmisartan Tablets, 80 mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.